PHOTO
A general view taken on February 8, 2022 shows the AstraZeneca facility for biological medicines in Södertälje, south of Stockholm, Sweden. - AstraZeneca’s new facility in Sweden located in Södertälje was inaugurated last December and is dedicated to the production of next generation biological drugs such as Evusheld, a Covid-19 preventative monoclonal antibody treatment for immunocompromised people. (Photo by Jonathan NACKSTRAND / AFP)
Anglo-Swedish pharmaceuticals giant AstraZeneca on Tuesday agreed to buy US biopharma firm Fusion for up to $2.4 billion, in the group's latest expansion into cancer treatments.
"The acquisition marks a major step forward in AstraZeneca delivering on its ambition to transform cancer treatment and outcomes for patients by replacing traditional regimens like chemotherapy and radiotherapy with more targeted treatments," the company said in a statement.
